Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: P2/MS is known as a simple, accurate, and noninvasive marker for determination of the degree of hepatic fibrosis in patients with viral hepatitis. We aimed to validate P2/MS in patients with HCC. Methods: Consecutive HCC patients who underwent surgical resection between June 2007 and March 2009 at Seoul National University Hospital were enrolled. Fibrosis stage was reviewed and assessed according to METAVIR scoring. P2/MS values [platelet count (109/L)]2/ [monocyte fraction (%)×segmented neutrophil fraction (%)] and other noninvasive fibrosis scoring systems were calculated. Results: A total of 171 patients were included; seven patients with METAVIR F1, 31 with F2, 41 with F3, and 92 with F4. The area under the receiver-operating characteristic curve of P2/MS was 0.804 [95% confidence interval (CI), 0.681~0.927] for detection of significant fibrosis (F2-F4) and 0.769 (95% CI, 0.698~0.839) for detection of histological cirrhosis (F4). At a value < 62, P2/MS detected significant fibrosis with a specificity of 85.7% (95% CI, 42.0~99.2) and a positive likelihood ratio of 4.268 (95% CI, 0.692~26.309); and at a value > 115, P2/MS ruled out significant fibrosis with a sensitivity of 90.2% (95% CI, 84.4~94.1) and a negative likelihood ratio of 0.34 (95% CI, 0.106~0.095). P2/MS had a superior efficacy for detection of hepatic fibrosis in patients with HCC compared to the other noninvasive panels. Conclusions: P2/MS can accurately detect fibrosis in patients with HCC. Thus, P2/MS might be utilized as a noninvasive index reflecting the degree of hepatic fibrosis in HCC patients.
Abstract
Background/Aims: P2/MS is known as a simple, accurate, and noninvasive marker for determination of the degree of hepatic fibrosis in patients with viral hepatitis. We aimed to validate P2/MS in patients with HCC. Methods: Consecutive HCC patients who underwent surgical resection between June 2007 and March 2009 at Seoul National University Hospital were enrolled. Fibrosis stage was reviewed and assessed according to METAVIR scoring. P2/MS values [platelet count (109/L)]2/ [monocyte fraction (%)×segmented neutrophil fraction (%)] and other noninvasive fibrosis scoring systems were calculated. Results: A total of 171 patients were included; seven patients with METAVIR F1, 31 with F2, 41 with F3, and 92 with F4. The area under the receiver-operating characteristic curve of P2/MS was 0.804 [95% confidence interval (CI), 0.681~0.927] for detection of significant fibrosis (F2-F4) and 0.769 (95% CI, 0.698~0.839) for detection of histological cirrhosis (F4). At a value < 62, P2/MS detected significant fibrosis with a specificity of 85.7% (95% CI, 42.0~99.2) and a positive likelihood ratio of 4.268 (95% CI, 0.692~26.309); and at a value > 115, P2/MS ruled out significant fibrosis with a sensitivity of 90.2% (95% CI, 84.4~94.1) and a negative likelihood ratio of 0.34 (95% CI, 0.106~0.095). P2/MS had a superior efficacy for detection of hepatic fibrosis in patients with HCC compared to the other noninvasive panels. Conclusions: P2/MS can accurately detect fibrosis in patients with HCC. Thus, P2/MS might be utilized as a noninvasive index reflecting the degree of hepatic fibrosis in HCC patients.
참고문헌 (29)
- Lok AS, "Hepatitis B: liver fibrosis and hepatocellular carcinoma", Gastroenterol Clin Biol, 33, pp.911~915 (2009)
- Matsumura H, "Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment", J Viral Hepat, 7, pp.268~275 (2000)
- Pawlik TM, "Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma", Arch Surg, 140, pp.450~457 (2005)
- Greene FL, "AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 6thed", pp.469~ (2002), Springer
- Forner A, "Current strategy for staging and treatment: the BCLC update and future prospects", Semin Liver Dis, 30, pp.61~74 (2010)
- Dienstag JL, "The role of liver biopsy in chronic hepatitis C", Hepatology, 36(1), pp.S152~S160 (2002)
- Bedossa P, "Sampling variability of liver fibrosis in chronic hepatitis C", Hepatology, 38, pp.1449~1457 (2003)
- Bravo AA, "Liver biopsy", N Engl J Med, 344, pp.495~500 (2001)
- Spinzi G, "Liver biopsy", N Engl J Med, 344, pp.2030~ (2001)
- Bruix J, "Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Ziol M, "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C", Hepatology, 41, pp.48~54 (2005)
- Friedrich-Rust M, "Performance of transient elastography for the staging of liver fibrosis: a meta-analysis", Gastroenterology, 134, pp.960~974 (2008)
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
- Sheth SG, "AST", ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection, 1998, pp.93, 44~48
- Poynard T, "Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups", J Viral Hepat, 4, pp.199~208 (1997)
- Lee JH, "Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virus-related chronic liver disease patients", J Viral Hepat, 16, pp.444~452 (2009)
- Kim BK, "External validation of P2", MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients, 2010, pp.55, 2636~2643
- Kim BK, "Prospective validation of P2", MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis, 2010, pp.30, 860~866
- Vallet-Pichard A, "FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
- Islam S, "Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers", Scand J Gastroenterol, 40, pp.867~872 (2005)
- Borroni G, "Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C", Aliment Pharmacol Ther, 24, pp.797~804 (2006)
- Shah AG, "Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 7, pp.1104~1112 (2009)
- Bedossa P, "An algorithm for the grading of activity in chronic hepatitis C", Hepatology, 24, pp.289~293 (1996), The METAVIR Cooperative Study Group
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update", Hepatol Int, 2, pp.263~283 (2008)
- Wai CT, "Non-invasive models for predicting histology in patients with chronic hepatitis B", Liver Int, 26, pp.666~672 (2006)
- Lin CS, "Retrospective evaluation of serum markers APRI and AST", ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma, 2008, pp.47, 569~575
- Pol S, "Reversibility of hepatitis C virus-related cirrhosis", Hum Pathol, 35, pp.107~112 (2004)
- Murphy JR, "Statistical errors in immunologic research", J Allergy Clin Immunol, 114, pp.1259~1263 (2004)